The Union Ministry of Health and Family Welfare has proposed incorporating Good Storage and Distribution Practices (GSDP) guidelines for pharmaceutical products into the Drugs Rules, 1945, in a move aimed at strengthening quality control across India's medicine supply chain.
The Ministry announced the proposal on November 19, 2026, stating that the framework is intended to help maintain the quality, safety, efficacy and integrity of pharmaceutical products from the manufacturer or importer to the point of supply to patients.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: Proposal to incorporate Good Storage and Distribution Practices into the Drugs Rules, 1945.
Location: India.
Authority/Organisation: Union Ministry of Health and Family Welfare and CDSCO.
Action Taken: Draft amendment proposed, with objections and suggestions invited from stakeholders and the public.
- Impact: Could strengthen medicine quality assurance, supply-chain accountability and regulatory oversight.
The proposed framework builds on guidance developed by the Central Drugs Standard Control Organisation (CDSCO). It covers important stages of the pharmaceutical distribution process, including procurement, purchasing, storage, transportation, distribution, documentation and record-keeping.
According to the Ministry, medicines can face quality-related risks even after leaving manufacturing facilities if appropriate storage and transportation conditions are not maintained. The proposed practices seek to address risks such as deterioration, contamination, product mix-ups, falsification, diversion and unauthorised distribution.
The draft amendment proposes compliance requirements for entities holding relevant drug licences. These include manufacturers, importers, wholesalers, distributors, stockists and other participants involved in the pharmaceutical distribution chain.
Editorial Analysis
Why This Matters
Medicine quality: Appropriate storage and transportation conditions are important for maintaining pharmaceutical product quality. Patient safety: Reducing the risk of deterioration, contamination and product mix-ups can support safer access to medicines. Supply-chain accountability: Better records and traceability can help identify how products move through distribution networks. Regulatory oversight: The proposed requirements could give drug-control authorities stronger grounds for inspection and enforcement. Industry responsibility: Relevant licence holders may face clearer compliance obligations if the draft is finalised.
The proposed framework is also expected to strengthen inspection and enforcement by Central and State drug-control authorities. Better documentation, record-keeping and traceability could help regulators monitor how pharmaceutical products are handled and moved through the supply chain.
The government has invited objections and suggestions from stakeholders and members of the public before finalising the proposal. Submissions can be sent to the Ministry of Health and Family Welfare through the prescribed postal or email channels.
The proposal is an effort to extend pharmaceutical quality assurance beyond manufacturing and strengthen safeguards during storage, transportation and distribution. However, the draft provisions will take effect only after the government completes the consultation process and publishes the final rules in the Official Gazette.


